Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024772 · ClinicalTrials.gov registry record · Phase 3
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
A Phase 3 study, sponsored by Thomas Jefferson University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT06024772 is a Phase 3 study that has not yet begun recruiting, run by Thomas Jefferson University. The registered enrollment target is 300 participants.
The verdict
NCT06024772, a Phase 3 study, has not yet begun recruiting, sponsored by Thomas Jefferson University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.
Interventions
- PROCEDURE Biopsy of Prostate
- PROCEDURE Transrectal Ultrasound
- DRUG Perflutren lipid microsphere
- PROCEDURE ultiparametric Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06024772
The ClinicalTrials.gov registry entry for NCT06024772 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biopsy of Prostate is the first listed.
NCT06024772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06024772 about?
NCT06024772 is a clinical study titled "Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer". This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is in...
What is the current status of trial NCT06024772?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-07. Estimated completion is 2027-02.
What interventions are being tested in trial NCT06024772?
The interventions under investigation include: Biopsy of Prostate (PROCEDURE), Transrectal Ultrasound (PROCEDURE), Perflutren lipid microsphere (DRUG), ultiparametric Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06024772?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.